Quant-iT™ microRNA Assay Kit
Use 96- and 384-well Microplates for Fluorescence-based Assays with Quant-iT assays for optimal results
Quant-iT™ microRNA Assay Kit
Invitrogen™

Quant-iT™ microRNA Assay Kit

Quant-iT microRNA Assay Kitアッセイキットを使用すれば、塩類、遊離ヌクレオチド、溶媒、界面活性剤、タンパク質などの一般的な汚染物質が存在する場合でも、miRNAを検出するmicroRNA詳細を見る
製品番号(カタログ番号)数量
Q328821 kit
製品番号(カタログ番号) Q32882
価格(JPY)
97,700
Each
お問い合わせください ›
数量:
1 kit
Quant-iT microRNA Assay Kitアッセイキットを使用すれば、塩類、遊離ヌクレオチド、溶媒、界面活性剤、タンパク質などの一般的な汚染物質が存在する場合でも、miRNAを検出するmicroRNA(miRNA)検出キットにより、microRNAを簡単かつ正確に定量することができます。このアッセイは rRNAや大きなmRNA(>1,000 bp)よりも microRNAに対して高い選択性を示します。

miRNAのみを選択できるわけではありませんが、アッセイ試薬を用いれば、mRNAの存在下であっても、供給されたプロトコルに従ってわずか0.5 ngのレベルまで、純粋サンプル中のmiRNAを高い再現性で定量することが可能です。

Quant-iT microRNA Assay Kitの特長は以下のとおりです:
• マイクロプレートウェル中のわずか0.5 ngのmiRNAを高感度で検出。
•5~500 ng/mLのコアダイナミックレンジ。
•50 ng/mL~100 μg/mLのサンプル濃度で正確な結果を得られます。

Quant-iT microRNAアッセイキットには、濃縮アッセイ試薬、希釈バッファー、および希釈済みmiRNA標準液が付属しています。試薬を1:200で希釈し、200 μLをマイクロプレートのウェルに充填します。1~20 μLのサンプルを加えて混合し、蛍光を読み取ります。サンプル調製から測定まで室温で行うことができ、シグナルは約3時間安定しています。アッセイの許容範囲は、200 μLのアッセイボリューム中、含有サンプル量1~20 μLです。そのため50 ng/mL~100 μg/mLの初期サンプル濃度で正確な結果を得ることができます。
研究用にのみ使用できます。診断用には使用いただけません。
仕様
アッセイmicroRNA定量
励起/発光498/518
使用対象 (装置)蛍光光度計、マイクロプレートリーダー
反応数1,000(200 μLアッセイ容量)
製品ラインQuant-iT
定量範囲1~100 ng
数量1 kit
検出法蛍光
Unit SizeEach

よくあるご質問(FAQ)

Why am I getting negative fluorescence values with my Qubit Assays?

Negative fluorescence is a physical impossibility. It is an artifact from software autocorrecting for background signal. This means your reader is picking up and subtracting out background light at the cost of your data. Make sure to do a buffer-only control and assess the type of signal. You may need to switch to a different plate.

引用および参考文献 (5)

引用および参考文献
Abstract
MicroRNA detection based on duplex-specific nuclease-assisted target recycling and gold nanoparticle/graphene oxide nanocomposite-mediated electrocatalytic amplification.
Authors:Han Y, Qiu Z, Nawale GN, Varghese OP, Hilborn J, Tian B, Leifer K
Journal:Biosens Bioelectron
PubMed ID:30611105
DNA technology based bio-responsive nanomaterials have been widely studied as promising tools for biomedical applications. Gold nanoparticles (AuNPs) and graphene oxide (GO) sheets are representative zero- and two-dimensional nanomaterials that have long been combined with DNA technology for point-of-care diagnostics. Herein, a cascade amplification system based on duplex-specific nuclease (DSN)-assisted ... More
A universal fluorescence-based toolkit for real-time quantification of DNA and RNA nuclease activity.
Authors:Sheppard EC, Rogers S, Harmer NJ, Chahwan R
Journal:Sci Rep
PubMed ID:31222049
DNA and RNA nucleases play a critical role in a growing number of cellular processes ranging from DNA repair to immune surveillance. Nevertheless, many nucleases have unknown or poorly characterized activities. Elucidating nuclease substrate specificities and co-factors can support a more definitive understanding of cellular mechanisms in physiology and disease. ... More
Differences in the miRNA signatures of chronic musculoskeletal pain patients from neuropathic or nociceptive origins.
Authors:Dayer CF, Luthi F, Le Carré J, Vuistiner P, Terrier P, Benaim C, Giacobino JP, Léger B
Journal:PLoS One
PubMed ID:31276478
The quality of life for millions of people worldwide is affected by chronic pain. In addition to the effect of chronic pain on well-being, chronic pain has also been associated with poor health conditions and increased mortality. Due to its multifactorial origin, the classification of pain types remains challenging. MicroRNAs ... More
Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells.
Authors:Cristofolini T, Dalmina M, Sierra JA, Silva AH, Pasa AA, Pittella F, Creczynski-Pasa TB
Journal:Mater Sci Eng C Mater Biol Appl
PubMed ID:32228895
Breast cancer is a major cause of death among women worldwide. Resistance to conventional therapies has been observed in HER2-positive breast cancer patients, indicating the need for more effective treatments. Small interfering RNA (siRNA) therapy is an attractive strategy against HER2-positive tumors, but its success depends largely on the efficient ... More
Identification and Validation of MicroRNA Profiles in Fecal Samples for Detection of Colorectal Cancer.
Authors:Duran-Sanchon S, Moreno L, Augé JM, Serra-Burriel M, Cuatrecasas M, Moreira L, Martín A, Serradesanferm A, Pozo À, Costa R, Lacy A, Pellisé M, Lozano JJ, Gironella M, Castells A
Journal:Gastroenterology
PubMed ID:31622624
Screening for colorectal cancer (CRC) is effective in the population at average risk. The most extended strategy in organized programs involves the fecal immunochemical test, which is limited by low sensitivity for the detection of advanced adenomas (AAs). We aimed to identify microRNA (miRNA) signatures in fecal samples that identify ... More